Breaking down KRAS: small-molecule degraders for cancer therapy

  • Signal Transduct Target Ther. 2025 Mar 14;10(1):86. doi: 10.1038/s41392-025-02172-4.
Tina Kos  1  2  3 ,  Dieter Saur  4  5  6  7
Affiliations
  • 1. Chair of Translational Cancer Research and Institute of Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany.
  • 2. Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Im Neuenheim Feld 280, 69120, Heidelberg, Germany.
  • 3. Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Einsteinstr. 25, 81675, Munich, Germany.
  • 4. Chair of Translational Cancer Research and Institute of Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. [email protected].
  • 5. Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Im Neuenheim Feld 280, 69120, Heidelberg, Germany. [email protected].
  • 6. Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Einsteinstr. 25, 81675, Munich, Germany. [email protected].
  • 7. Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. [email protected].
PMID: 40082410 DOI: 10.1038/s41392-025-02172-4